Member Info for RayPointer

I would have thought that, at this stage, nobody knows what is the best interval between doses.
It certainly may vary by vaccine and possibly other variables such as age group.

I agree AB news will move the SP. This is obvious.
But why this obsession with the timing of news and its relationship to the SP.
We know there will be news when there is something the company have to say.
Trying to second guess when news will arrive and what it will be I would suggest is a pointless exercise for a research led company like Scancell.

But what we do know from experience is that work is continuing on a number of fronts
a) the delivery peptides
b) perhaps testing Covidity against Covid19 variants
c) perhaps Covidity development tasks such as a toxicity report
d) the new moditope target
e) final preparations for the modi1 trial
f) modi2 milestones in development
g) modi3 possibilities
h) whether scib2 is being re-engineeered with Avidimab
i) Avidmab further research
j) glycans mabs further research

We know that all are the above are probably going on and perhaps more besides.
But what a fantastic list for a company the size of Scancell.

What leads to frustrations in many shareholders is that, to them, it is not happening fast enough.
Add to that the frustrations that we don't know when cancer trials will restart.

Stay calm and support the Clarets (and Yellows) is what I say. TF, I couldn't resist :-)

AB, I take you points and it all depends what type of investor you are.

If you were a trader you would be considering buying now since it looks like the SP has hit a support level.
If you are someone who hops around different Covid19 shares you would be getting impatient and thinking of your next hop. No news so nothing is happening and you start fretting.
If you a long termer like myself you should be quite happy since you have 2 major investors who have done their due diligence and invested to such an extent that money is no worry for the next 2-3 years. That to me is a double whammy, validation of the science and the money to back it up.

Each type of investor have different risks to consider. Which type of investor are you?

"Given Scancell has been around for quite a long time, what could be the catatlyst for new investors at the moment? "
Vulpes and Redmile would say the science is the catalyst.

Apart from the odd sell by TW to buy pizza dough it looks like solid buying now.
I don't quite know how this transfer of shares was arranged but it certainly was orchestrated. The sellers got a good and stable price and the buyers were happy with a 13p entry price

I think our friend TW gave a 17p target followed by a Sell recommendation :-)

With Lindy and patents, you have to wait to get more details. "Immunotherapy" doesn't give much of a clue. There is so much research going on.
She also said that the Immunobody patent will change (or a new patent) for the inclusion of Avidimab.

It will also be interesting to see if a separate patent is issued for the delivery peptides. I believe the Nottingham School of Pharmacy (or maybe Nottingham Uni) own the IP for the delivery method. However, as we know, an Immunobody vaccine requires to enter soft muscle cells and also APCs so the actual combination of peptides used for this may require a patent, who knows?

I can't see any patents specific to Covidity itself since
a) the revised Immunobody patent will cover Covidity and all future Immunobody vaccines (including SCIB2) for the Avidimab inclusion
b) the delivery peptides should be common to all Immunobody vaccines
c) I can't see any of the Covidity targets being patented since there is so much research on Covid19 targets in the public domain but again who knows?

Also Copper miners in Australia have noticed elephants digging at the copper tailings with their trunks. Naturalists are bemused by their presence and more so because the elephants appear to roar with South African accents :-)

I seem to remember that the AGM presentation talked about a new Moditope target. Perhaps that is the subject of the new patent.

"Last one" until the next one :-)

Looks like it might be Australia next but not this year.
Sounds very sensible to me to cement Zambian operations before going elsewhere.

From the 6 month operations update

"The success in Zambia to date is a clear demonstration of the team's technical know-how and IP when it comes to processing copper tailings and the Company will continue to assess opportunities to implement the copper strategy on a global scale, replicating this success in new jurisdictions. "

It looks like it is only a matter of time before the Copper strategy finds new homes.

It could be that previously Leon was hesitant about calling the Copper projects "Copper and Cobalt" since the Cobalt extraction process was still being developed and perfected. Perhaps now he is more confident that the Cobalt extraction process is economic and will work. We await figure, but they may not be in the too distant future with concentrates arriving soon from project Roan.

https://www.newscientist.com/article/dn28092-hidden-viral-protein-brings-universal-flu-jab-closer/

This article is about flu viruses and a possible constant protein.

"But while your immune system targets these decoy proteins, other proteins that the immune system ignores get on with replicating the virus and causing infections. Because they have precise mechanical jobs to do, these hardly vary between flu virus families and remain unchanged for years. In theory, if we could encourage people’s immune response to recognise and target these constant proteins, that immunity might work permanently against all kinds of flu."

This sounds like it could be the equivalent of the N protein in Coronaviruses as far as constant targets are concerned.
We await to see if the combination of Immunobody and Avidimab produces T Cells that can knock out a Coronavirus through targeting N protein epitopes alone. But if this works well then possibly other types of virus could be eliminated in a similar way. Of course, the epitopes need to be found on the targeted protein but the principle is the same.

There is no mention of T Cells in this article, but I suspect that this current pandemic may cause virologists to look at both antibodies and T Cells when considering approaches to attack viruses. We have seen so many articles that stress the longevity of memory T Cells and their existence long after the antibodies have disappeared.

There's a load of info about TW in this series of articles.

https://sharetipstersuncovered.wordpress.com/author/tipsterinvestigators/

Worth reading if you are ever interested in any of his tips.

I don't see a 5% dilution as a big problem (if that's what it is).
The CLNs are bound to be converted at some point and we have a new investor on board buying at a virtually undiscounted price. That purchase price is after a very good sustained rise in the the SP.
It also gives us all a chance to grab more shares close to 13p. That's if you are that way inclined of course and I am that way inclined.

"Can't really remember why I bought in here anybody remind me???"
Because you are a genius!

But we've done a trade deal with ADVFN :-)
The snippets are tariff free.

"The first of the processing facilities has entered its construction phase at Project Roan which targets an annual production rate of 10 000 tonnes of equivalent copper units. The processing facility will be commissioned over three phases to accelerate the delivery of copper units for further refining to Jubilee's Sable Refinery. Phase 1 is expected to commence delivery of the first copper units to Sable Refinery by end February 2021 which results in the first significant increase in production at the Sable Refinery targeting to achieve 400 tonnes per month. Sable Refinery is fully operational and ready to commence refining of Project Roan's material and has already achieved earnings of GBP 1. 8 million (ZAR 39 million) from production during this phase."

This is to me is one of the best bits of the RNS. Copper concentrate will start arriving at Sable from project Roan as early as end of Feb 21.

The riders of Roan will soon start arriving :-)

I'm guessing that if the RBD (receptor binding domain) on the Spike protein remains the same then vaccines that rely on producing antibodies to attach to the RBD should still be able to neutralise the virus.